Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  British Journal of Clinical Pharmacology

• Publication date

  2012-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1365-2125.2012.04205.xPMID 22300396PMCID PMC3477348
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals

  2011cited by this paper
• Interaction between Artemether-Lumefantrine and Nevirapine-Based Antiretroviral Therapy in HIV-1-Infected Patients

  2011cited by this paper
• Piraña and PCluster: A modeling environment and cluster infrastructure for NONMEM

  2011cited by this paper
• Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine

  2011cited by this paper
• Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models

  2011cited by this paper
• Population Pharmacokinetic-Pharmacogenetic Study of Nevirapine in HIV-Infected Cambodian Patients

  2010cited by this paper
• Lack of association between stavudine exposure and lipoatrophy, dysglycaemia, hyperlactataemia and hypertriglyceridaemia: a prospective cross sectional study

  2010cited by this paper
• Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients

  2010cited by this paper
• Meta-analysis of individual participant data: rationale, conduct, and reporting

  2010cited by this paper
• Randomized controlled trial of trained patient-nominated treatment supporters providing partial directly observed antiretroviral therapy

  2010cited by this paper
• Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa

  2010cited by this paper
• NONMEM User’s Guides. (1989–2009)

  2009cited by this paper
• Influence of darunavir coadministration on nevirapine pharmacokinetics in HIV‐infected patients: a population approach

  2009cited by this paper
• Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes.

  2009cited by this paper
• Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy.

  2008cited by this paper
• Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach.

  2008cited by this paper
• Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients

  2008cited by this paper
• Mechanism-based concepts of size and maturity in pharmacokinetics.

  2008cited by this paper
• Bayesian graphical models for regression on multiple data sets with different variables

  2008cited by this paper
• Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa

  2008cited by this paper
• Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients.

  2008cited by this paper
• CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children

  2007cited by this paper
• Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies

  2007cited by this paper
• Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B

  2007cited by this paper
• Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis.

  2007cited by this paper
• Propagation of Population PK and PD Information Using a Bayesian Approach: Dealing with Non-Exchangeability

  2006cited by this paper
• Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus‐infected individuals

  2005cited by this paper
• Propagation of Population Pharmacokinetic Information Using a Bayesian Approach: Comparison with Meta-Analysis

  2005cited by this paper
• Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients

  2005cited by this paper
• Nevirapine and Efavirenz Pharmacokinetics and Covariate Analysis in the 2Nn Study

  2005cited by this paper
• Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.

  2004cited by this paper
• Perl-speaks-NONMEM (PsN) - a Perl module for NONMEM related programming

  2004cited by this paper
• Modeling Interindividual Variation in Physiological Factors Used in PBPK Models of Humans

  2003cited by this paper
• An LC-MS-MS method for the determination of nevirapine, a non-nucleoside reverse transcriptase inhibitor, in human plasma.

  2003cited by this paper
• MDR1 and CYP3A4 polymorphisms among African, Indian, and white populations in KwaZulu‐Natal, South Africa

  2003cited by this paper
• Use of Prior Information to Stabilize a Population Data Analysis

  2002cited by this paper
• Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals.

  2002cited by this paper
• Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays.

  2001cited by this paper
• The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals

  2000cited by this paper
• Inter-study variability in population pharmacokinetic meta-analysis: when and how to estimate it?

  2000cited by this paper
• The Combination of Population Pharmacokinetic Studies

  2000cited by this paper
• Pharmacokinetics of nevirapine and lamivudine in patients with HIV-1 infection

  2000cited by this paper
• Disposition and biotransformation of the antiretroviral drug nevirapine in humans.

  1999cited by this paper
• Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers

  1999cited by this paper
• Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM.

  1999cited by this paper
• Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1.

  1999cited by this paper
• Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450.

  1999cited by this paper
• Population Pharmacokinetics of Nevirapine, Zidovudine, and Didanosine in Human Immunodeficiency Virus-Infected Patients

  1999cited by this paper
• The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin.

  1999cited by this paper
• Rapid determination of nevirapine in human plasma by ion-pair reversed-phase high-performance liquid chromatography with ultraviolet detection.

  1998cited by this paper
• Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy

  1994cited by this paper

• Population-based study of pharmacogenetics and pharmacokinetics in Southern African patients with multidrug-resistant tuberculosis (PoPG): a protocol for the Namibian cohort

  2026cites this paper
• Population pharmacokinetics of ritonavir as a booster of lopinavir, atazanavir, or darunavir in African children with HIV

  2025cites this paper
• Revolutionizing Patient-Reported Outcomes Analysis for Oncology Drug Development Using Population Models

  2025cites this paper
• Towards Model-Informed Precision Dosing of Voriconazole: Challenging Published Voriconazole Nonlinear Mixed-Effects Models with Real-World Clinical Data

  2023cites this paper
• Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis

  2023cites this paper
• Pharmacokinetics of standard versus high-dose isoniazid for treatment of multidrug-resistant tuberculosis.

  2022cites this paper
• Efficient and relevant stepwise covariate model building for pharmacometrics

  2022cites this paper
• Population pharmacokinetics of ethambutol in African children: a pooled analysis

  2022cites this paper
• Abacavir pharmacokinetics in African children living with HIV: A pooled analysis describing the effects of age, malnutrition and common concomitant medications

  2021cites this paper
• Evaluation of the estimation and classification performance of NONMEM when applying mixture model for drug clearance

  2021cites this paper
• A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis

  2021cites this paper
• Drug-drug Interactions between and Commonly-used Antiretroviral 2 Treatment: An Individual Participant Data Population Pharmacokinetic Meta-Analysis.

  2020cites this paper
• An Individual Participant Data Population Pharmacokinetic Meta-analysis of Drug-Drug Interactions between Lumefantrine and Commonly Used Antiretroviral Treatment

  2020cites this paper
• Development and Application of a Mechanistic Population Modeling Approach to Describe Abemaciclib Pharmacokinetics

  2020cites this paper
• A population pharmacokinetics analysis assessing the exposure of raltegravir once‐daily 1200 mg in pregnant women living with HIV

  2020cites this paper
• Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modelling

  2019cites this paper
• Population Pharmacokinetic‐Pharmacodynamic Modeling for Propofol Anesthesia Guided by the Bispectral Index (BIS)

  2019cites this paper
• Population pharmacokinetic meta-analysis of individual data to design the first randomized efficacy trial of vancomycin in neonates and young infants.

  2019cites this paper
• Population Pharmacokinetic Properties of Sulfadoxine and Pyrimethamine: a Pooled Analysis To Inform Optimal Dosing in African Children with Uncomplicated Malaria

  2018cites this paper
• Population Pharmacokinetics of the Antimalarial Amodiaquine: a Pooled Analysis To Optimize Dosing

  2018cites this paper
• A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400 mg in Pregnant Women

  2018influential citation
• Optimization of the strength of the efavirenz/lamivudine/abacavir fixed-dose combination for paediatric patients

  2017cites this paper
• Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children

  2016cites this paper
• The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children

  2016cites this paper
• Determinants of nevirapine plasma levels and clinical outcomes in HIV patients at Kenyatta National Hospital, Kenya.

  2016cites this paper
• Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling

  2014cites this paper
• Population Pharmacokinetics of Nevirapine in Thai HIV-Infected Patients

  2014cites this paper
• Population Pharmacokinetic-Pharmacodynamic Modelling of Antimalarial Treatment

  2014influential citation
• Population pharmacokinetic model to analyze nevirapine multiple-peaks profile after a single oral dose

  2014cites this paper
• Systematic Review of Population Pharmacokinetic Analyses of Imatinib and Relationships With Treatment Outcomes

  2013cites this paper